Compare · POAS vs TMO
POAS vs TMO
Side-by-side comparison of Phaos Technology Holdings (Cayman) Limited (POAS) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both POAS and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $256.15B, about 48292.6x POAS ($5.3M).
- TMO has been more active in the news (9 items in the past 4 weeks vs 2 for POAS).
- TMO has more recent analyst coverage (25 ratings vs 0 for POAS).
- Company
- Phaos Technology Holdings (Cayman) Limited
- Thermo Fisher Scientific Inc
- Price
- -
- -
- Market cap
- $5.3M
- $256.15B
- 1M return
- -
- +0.17%
- 1Y return
- -
- +21.89%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- AMEX
- NYSE
- IPO
- 2025
- News (4w)
- 2
- 9
- Recent ratings
- 0
- 25
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest POAS
- SEC Form 6-K filed by Phaos Technology Holdings (Cayman) Limited
- Phaos Technology Holdings (Cayman) Limited Provides Required Going Concern Disclosure
- SEC Form 6-K filed by Phaos Technology Holdings (Cayman) Limited
- Phaos Technology Holdings (Cayman) Limited Announces Filing of Annual Report on Form 20-F for Fiscal Year 2026
- Phaos Technology Holdings (Cayman) Limited Announces One-For-Fifteen Reverse Stock Split
- SEC Form 6-K filed by Phaos Technology Holdings (Cayman) Limited
- Phaos Technology Holdings (Cayman) Limited Announces Entry Into Securities Purchase Agreement for an Equity Facility of Up to US$10 Million
- SEC Form 6-K filed by Phaos Technology Holdings (Cayman) Limited
- Phaos Technology Holdings (Cayman) Limited Announces Update on Involvement of Related Parties
- SEC Form 6-K filed by Phaos Technology Holdings (Cayman) Limited
Latest TMO
- President & COO Pettiti Gianluca sold $2,898,969 worth of shares (4,133 units at $701.42) as part of a pre-agreed trading plan and exercised 3,733 shares at a strike of $309.63, decreasing direct ownership by 2% to 22,816 units (SEC Form 4)
- Thermo Fisher Scientific to Participate in UBS 2026 CEO Call Series on November 19, 2026
- Thermo Fisher Scientific Authorizes $5 Billion of Share Repurchases
- Thermo Fisher Scientific Announces Quarterly Dividend
- SEC Form SCHEDULE 13G filed by Thermo Fisher Scientific Inc
- Director Sperling Scott M gifted 3,490 shares, decreasing direct ownership by 5% to 65,989 units (SEC Form 4)
- Sr. VP and Chief HR Officer Britt Lisa P. sold $1,999,960 worth of shares (2,831 units at $706.45) (SEC Form 4)
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Leadership Update
- SEC Form 10-Q filed by Thermo Fisher Scientific Inc
- SEC Form 8-K filed by Thermo Fisher Scientific Inc